Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 6, 2008, Pages 605-610

  Busti, Anthony J ^a,b,f   Bain, Amy M ^a,b   Hall, Ronald G ^a,b,c   Bedimo, Roger G ^b,c   Leff, Richard D ^a,d   Meek, Claudia ^a,d   Mehvar, Reza ^d,e  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d CHILDREN S MEDICAL CENTER   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f TEXAS TECH UNIVERSITY   (United States)

Author keywords

Atazanavir; Drug interaction; Fosamprenavir; Pharmacokinetics; Ritonavir; Rosuvastatin

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DRUG METABOLITE; FOSAMPRENAVIR PLUS RITONAVIR; N DESMETHYL ROSUVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; ROSUVASTATIN LACTONE; UNCLASSIFIED DRUG; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CARBAMIC ACID DERIVATIVE; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OLIGOPEPTIDE; ORGANOPHOSPHATE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RITONAVIR; SULFONAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; HUMAN; JAUNDICE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PATIENT COMPLIANCE; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; BLOOD; DRUG COMBINATION; DRUG INTERACTION;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CARBAMATES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; OLIGOPEPTIDES; PHOSPHORIC ACID ESTERS; PROSPECTIVE STUDIES; PYRIDINES; PYRIMIDINES; RITONAVIR; SULFONAMIDES;

EID: 53249156549     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31817b5b5a     Document Type: Article

References (25)

1. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV) -infected adults receiving antiretroviral therapy: recommendations of the HIV medicine association of the Infectious Disease Society of America and the adult Aids Clinical Trials Group. Clin Infec Dis. 2003;37:613-627.
2. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-134. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdoles centsGL.pdf. Accessed February 26, 2008.
3. Tibotec, Inc. Prezista (darunavir) package insert. Raritan, NJ; 2006.
4. Fichentenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV sero-negative volunteers: ACTG Study A5047. AIDS. 2002;16:569-577.
5. Aberg JA, Rosenkranz SL, Fichtenbaum CJ, et al. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG study A5108. AIDS. 2006;20:725-729.
6. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003;25:2822-2835.
7. Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS. 2005;19:1103-1108.
8. Hoody DW, Kiser JJ, Predhomme JA, et al. Drug-drug interaction between lopinavir/ritonavir and rosuvastatin. Presented at the 14th Conference on Retroviruses and Opportunistic Infections; February 25 to 28, 2007; Los Angeles, CA.
9. van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetic and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther. 2007;12:1127-1132.
10. Guidance for industry - drug interaction studies - study design, data analysis, and implications for dosing and labeling (draft open for comment). September 2006. Available at: http://www.fda.gov/cder/ guidance/6695dft.htm. Accessed February 26, 2008.
11. Bristol-Myers Squibb. Reyataz (atazanavir) package insert. Princeton, NJ: March 2007.
12. GlaxoSmithKline. Lexiva (fosamprenavir) package insert. Research Triangle Park, NC: February 2007.
13. Abbott Laboratories. Norvir (ritonavir) package insert. North Chicago, IL: January 2006.
14. Huang L, Wang Y, Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos. 2006;34:738-742.
15. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005;7:E118-E133.
16. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther. 2006;109:137-161.
17. Merino G, Alvarez AI, Pulido MM, et al. Breast cancer resistance protein (BCRP/ABCG2) transports fuoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006;34:690-695.
18. Weiss J, Rose J, Storch CH, et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother. 2007;59:238-245.
19. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76:167-177.
20. Campbell SD, de Morais SM, Xu JJ. Inhibition of human organic anion transporting polypeptide OATP1B1 asa mechanism of drug induced hyperbilirubinemia. Chem Biol Interact. 2004;150:179-187.
21. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effects of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75:455-463.
22. Kumar GN, Grabowski B, Lee R, et al. Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538). Drug Metab Dispos. 1996;24:615-617.
23. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol. 1998;46:111-116.
24. Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33:1729-1739.
25. Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33:1729-1739.